Market Intelligence, Clinical Progress, and High-Purity Reagents for Macrophage Checkpoint Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD47 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD47 ECD-Fc / Mutant Protein (Human/Cyno/Mouse). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CD47 Products |
| Gene Delivery | CD47 Promise-ORF / Lentivirus Particles. Full-length ORF for stable cell line construction. Titer >10^8 TU/mL. Essential for flow cytometry cell-based assays. | View CD47 Products |
| Benchmark Ab | Anti-CD47 (Magrolimab Biosimilar). Recombinant IgG4 positive control. Sequence Verified. High Purity. | View CD47 Products |
| Validator | CD47 siRNA Set (three target-specific sequences). For knockdown verification and specificity checks. Sequence Verified. | View CD47 Products |
| Ligand / Related Target A | SIRPα ECD-Fc Protein. High-affinity ligand for competitive binding assays. HEK293 expressed. | View SIRPA Products |
| Related Target B | CD20 ECD-Fc Protein. Synergistic target for bispecific antibodies to drive tumor-specific binding and bypass RBC sink. | View CD20 Products |
| Combination Partner | PD-L1 Full-Length Protein (ECD-Fc available). For bispecific/TME modulation studies. Native conformation. | View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Toxicology Evaluation (Human/Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity and theoretical MW confirmed. Sequence Verified for GLP assay transfer. |
| RBC Hemagglutination / Target-Mediated Drug Disposition | Native glycosylation (HEK293) ensures accurate binding kinetics (SPR/BLI) for affinity-tuned bispecifics. Defined glycosylation pattern mimics tumor vs RBC epitopes. |
| SIRPα Competition & Affinity Tuning | SIRPα-FC chimeric protein with theoretical MW ~50kDa; SPR-ready for high-precision kinetic analysis against candidate mAbs. |
| Lack of Controls / Benchmark Abs | Clinical Benchmark Antibodies (Biosimilars) included with strictly controlled endotoxin levels (<0.1 EU/µg). |
| False Positives (Cellular Specificity) | Validated siRNA set included for cellular specificity checks. |
| Combination Therapy Validation | Matched PD-L1 and CD20 antigens for bispecific format confirmation; Endotoxin-controlled for macrophage activation assays. |
Live CD47 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD47 therapeutics has intensified, evolving from first-generation pan-CD47 blockers toward next-generation tumor-selective modalities. Following major setbacks with first-generation antibodies (e.g., Gilead's magrolimab) due to anemia-related toxicities and RBC sink effects, the field is pivoting to engineered formats that minimize red blood cell binding while maintaining tumor-associated macrophage (TAM) engagement. The next wave of R&D focuses on bispecific constructs (CD47xCD20, CD47xPD-L1), SIRPα-Fc fusion proteins, and conditionally active antibodies (pH-dependent or protease-cleavable masks). These advanced modalities aim to decouple tumor-specific macrophage phagocytosis from systemic erythrocyte toxicity, requiring rigorous in vitro assay screening using strictly quality-controlled antigens. As second-generation molecules enter Phase I, combination regimens with chemotherapy or ADCs are being explored to integrate "eat me" and "don't eat me" signals.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific (CD47 x TAA) | Innovent, ALX Oncology, Akeso, ImmuneOncia | Hematologic Malignancies, Solid Tumors (NSCLC, HCC) | Affinity Balancing (Need high-purity ECD-Fc for SPR and dual-target occupancy) |
| SIRPα-Fc Fusion | Trillium (Pfizer), ALX Oncology (ALX148) | MDS, AML, Head & Neck, Gastric | Receptor Blocking Assay (Need HEK293 expressed antigens and high-avidity bridge formation) |
| Masked / Conditionally Active mAb | CytomX, Mabspace | Solid Tumors | pH-dependent Binding Assay (Need sequence-verified antigens for pH 6.5 vs 7.4) |
| Monoclonal Antibody (Next-gen) | ALX Oncology, I-Mab, Gilead (Magrolimab) | MDS, AML, Solid Tumors | RBC Competition Assay (Need high-purity Human/Cyno CD47 to assess on-target toxicity) |
| SIRPα Antibody | OSE Immunotherapeutics | Solid Tumors | Epitope Binning vs CD47 (Need CD47 lentivirus transduced cells for flow cytometry) |
| CD47-SIRPα Fusion | ALX Oncology (ALX148) | Solid Tumors | High-Avidity Bridge Formation (Need SIRPα-FC with native glycosylation) |
Note: Some modalities overlap; the above snapshot captures key players and their primary assay requirements.